Wulfkuhle JD - Search Results

1

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, Brett LK, Wulfkuhle JD, Gallagher RI, Petricoin EF, Bender TP, Williams ME, Weber MJ. Jayappa KD, et al. Among authors: wulfkuhle jd. Blood Adv. 2017 Jun 13;1(14):933-946. doi: 10.1182/bloodadvances.2016004176. Blood Adv. 2017. PMID: 29034364 Free PMC article.

2

Proteomic applications for the early detection of cancer.

Wulfkuhle JD, Liotta LA, Petricoin EF. Wulfkuhle JD, et al. Nat Rev Cancer. 2003 Apr;3(4):267-75. doi: 10.1038/nrc1043. Nat Rev Cancer. 2003. PMID: 12671665 Review.

3

Proteomic approaches to the diagnosis, treatment, and monitoring of cancer.

Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF 3rd, Liotta L. Wulfkuhle JD, et al. Adv Exp Med Biol. 2003;532:59-68. doi: 10.1007/978-1-4615-0081-0_7. Adv Exp Med Biol. 2003. PMID: 12908550 Review.

4

Protein microarrays: molecular profiling technologies for clinical specimens.

Espina V, Mehta AI, Winters ME, Calvert V, Wulfkuhle J, Petricoin EF 3rd, Liotta LA. Espina V, et al. Proteomics. 2003 Nov;3(11):2091-100. doi: 10.1002/pmic.200300592. Proteomics. 2003. PMID: 14595807 Review.

5

STUDENTJAMA. Molecular technologies for personalized cancer management.

Hasan RK, Wulfkuhle JD, Liotta LA, Petricoin EF. Hasan RK, et al. Among authors: wulfkuhle jd. JAMA. 2004 Apr 7;291(13):1644-5. doi: 10.1001/jama.291.13.1644. JAMA. 2004. PMID: 15069056 No abstract available.

6

Clinical proteomics: revolutionizing disease detection and patient tailoring therapy.

Petricoin E, Wulfkuhle J, Espina V, Liotta LA. Petricoin E, et al. J Proteome Res. 2004 Mar-Apr;3(2):209-17. doi: 10.1021/pr049972m. J Proteome Res. 2004. PMID: 15113096 Review.

7

Protein microarray detection strategies: focus on direct detection technologies.

Espina V, Woodhouse EC, Wulfkuhle J, Asmussen HD, Petricoin EF 3rd, Liotta LA. Espina V, et al. J Immunol Methods. 2004 Jul;290(1-2):121-33. doi: 10.1016/j.jim.2004.04.013. J Immunol Methods. 2004. PMID: 15261576 Review.

8

Genomic and proteomic technologies for individualisation and improvement of cancer treatment.

Wulfkuhle J, Espina V, Liotta L, Petricoin E. Wulfkuhle J, et al. Eur J Cancer. 2004 Nov;40(17):2623-32. doi: 10.1016/j.ejca.2004.05.020. Eur J Cancer. 2004. PMID: 15541963 Review.

9

Reverse-phase protein microarrays for tissue-based analysis.

Speer R, Wulfkuhle JD, Liotta LA, Petricoin EF 3rd. Speer R, et al. Among authors: wulfkuhle jd. Curr Opin Mol Ther. 2005 Jun;7(3):240-5. Curr Opin Mol Ther. 2005. PMID: 15977421 Review.

10

Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays.

Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF 3rd. Wulfkuhle JD, et al. Nat Clin Pract Oncol. 2006 May;3(5):256-68. doi: 10.1038/ncponc0485. Nat Clin Pract Oncol. 2006. PMID: 16683004 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters